External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Haematology ASH 2021
Roche and Genentech at

ASH 2021

December 11 - December 14
Atlanta, USA / Virtual (Hybrid)
hematology.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Highlights
Coming soon
09:30 AM
Duration 10mins B207-B208
Cost-Effectiveness Analysis of Venetoclax Plus Azacitidine vs. Azacitidine in Newly Diagnosed Adult Patients With Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy From a United States Payer Perspective
Pratz K, Chai X, Xie J, Yin L, Nie X, Montez M, Iantuono E, Downs L, Ma E
Haematology - Oncology | Acute Myeloid Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Hall C1
Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination With Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Kumar SK, Harrison SJ, Cavo M, de La Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Onishi M, Ku G, Pothacamury R, Sehgal V, Masud A, Ross JA, Dobkowska E, Moreau P
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:00 PM
Duration 10mins Hall C1
Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma: updated results from an ongoing Phase I study
Trudel S, Cohen AD, Krishnan A, Fonseca R, Spencer A, Berdeja JG, Lesokhin A, Forsberg PA, Laubach JP, Costa LJ, Rodriguez-Otero P, Kaedbey R, Richter J, Mateos M-V, Thomas SK, Wong C, Li M, Choeurng V, Vaze A, Samineni D, Sumiyoshi T, Cooper J, Harrison S
Haematology - Oncology | Multiple Myeloma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Thomas Murphy Ballroom 1-2
Glofitamab as Monotherapy and in Combination with Obinutuzumab Induces High Complete Response Rates in Patients with Multiple Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Morschhauser F, Carlo-Stella C, Dickinson M, Phillips T, Houot R, Offner F, Haioun C, Corradini P, Hutchings M, Sureda A, Martinez-Lopez J, Wróbel T, Wu S-J, Lundberg L, Mulvihill E, Perez-Callejo D, Relf J, Panchal A, Humphrey K, Bachy E
Haematology - Oncology | Non Hodgkin Lymphoma - Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Thomas Murphy Ballroom 1-2
Glofitamab Step-Up Dosing Induces High Response Rates in Pts With R/R MCL, Most of Whom Had Failed Prior BTKi Therapy
Phillips T, Dickinson M, Morschhauser F, Bachy E, Crump M, Trnĕný M, Bartlett N, Zaucha J, Humphrey K, Perez-Callejo D, Lundberg L, Relf J, Filezac de L’Etang A, Carlile D, Clark E, Carlo-Stella C
Haematology - Oncology | Non Hodgkin Lymphoma - Mantle Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Thomas Murphy Ballroom 1-2
Mosunetuzumab in Combination With Lenalidomide has a Manageable Safety Profile and Encouraging Activity in Patients With Relapsed/Refractory Follicular Lymphoma: Initial Results From a Phase Ib Study
Morschhauser F, Bishton M, Eyre TA, Bachy E, Cartron G, Ysebaert L, Bobillo S, Gutierrez NC, Budde LE, Fox CP, Knapp A, Yaqub M, Wei MC, O'Hear C, Li H, Purev E, Townsend W
Haematology - Oncology | Non Hodgkin Lymphoma - Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Thomas Murphy Ballroom 1-2
Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline S, Giri P, Kuruvilla J, Canales M, Dietrich S, Fay K, Ku M, Nastoupil L, Wei MC, Yin S, Doral MY, Li C-C, Huang H, Negricea R, Penuel E, O'Hear C, Bartlett NL
Haematology - Oncology | Non Hodgkin Lymphoma - Follicular Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:00 PM
Duration 10mins B207-B208
Molecular Responses are Observed Across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax plus Azacitidine
Garcia JS, Wei AH, Jacoby MA, Fong CY, Borate U, Baer MR, Cunningham I, Odenike O, Jurcic JG, Nowak D, Peterlin P, Platzbecker U, Dunshee D, Zhou Y, Hoffman D, Sun Y, Popovic R, Ainsworth B, Naqvi K, Kye S, Hogdal L, Garcia-Manero G
Haematology - Oncology | Leukaemia & Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Sidney Marcus Auditorium
Outcomes in Patients with Poor-risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Azacitidine
Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD
Haematology - Oncology | Acute Myeloid Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:30 AM
Duration 10mins C211-C213
Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study
Negrier C, Mahlangu J, Lehle M, Chowdary P, Catalani O, Jimenez-Yuste V, Beckermann BM, Schmitt C, Hermans C, Ventriglia G, Windyga J, Kiialainen A, d'Oiron R, Moorehead P, Teodoro V, Shapiro AD, Oldenburg J
Haematology - Oncology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins C211-C213
Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry
Poon M-C, Lee A, Germini F, Keepanasseril A, Ibrahim Q, Nissen F, Sanabria F, Santos M, Iserman E, Matino D, Iorio A
Haematology - Oncology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins C211-C213
Surgical Experience from the Phase IIIb STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A with FVIII Inhibitors: Final Analysis
Castaman G, Windgya J, Alzahrani H, Robson S, Sanabria F, Howard M, Jimenez-Yuste V
Haematology - Oncology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
04:30 PM
Duration 10mins Thomas Murphy Ballroom 1-2
Glofitamab in Combination with Polatuzumab Vedotin: Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Hutchings M, Sureda A, Terol MJ, Bosch F, Corradini P, Stauffer Larsen T, Rueda Dominguez A, Panchal A, Bottos A, Wang Y, Filézac de L’Etang A, Tandon M, Sellam G, Gritti G
Haematology - Oncology | Non Hodgkin Lymphoma - Diffuse Large B-Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins Thomas Murphy Ballroom 3-5
Mosunetuzumab Plus Polatuzumab Vedotin has Promising Efficacy and a Favorable Safety Profile in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma: Updated Results from a Phase Ib/II Study
Budde LE, Olszewski A, Assouline S, Kamdar M, Diefenbach C, Ghosh N, Lossos IS, Mehta A, Sabry W, Dorritie K, Pham S, Xu J, Huw L-Y, To I, Oki Y, O'Hear C, Chavez J
Haematology - Oncology | Non Hodgkin Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 10mins B211-B212
Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome
Zeidan AM, Borate U, Pollyea DA, Brunner AM, Roncolato F, Garcia JS, Filshie RJ, Odenike O, Watson A-M, Bajel A, Naqvi K, Zha J, Hogdal L, Zhou Y, Hoffman D, Kye S, Garcia-Manero G
Haematology - Oncology | Leukaemia & Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:30 AM
Duration 10mins B312-B314
A Novel Methodology for Building Longitudinal, Patient-Centric Real World Datasets in Hemophilia A
Skinner MW, Hanson G, Xu T, Ofori-Asenso R, Ko RH, Cibelli E, Nissen F, Witkop M, Sanabria F, Shapiro AD
Haematology - Oncology | Hemophilia A

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:45 PM
Duration 10mins B308-B309
Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 Mutation in Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow M, McCloskey J, Smith CC, Schiller G, Bradley T, Tiu RV, Naqvi K, Dail M, Siddani S, Wang J, Chyla B, Lee P, Altman JK
Haematology - Oncology | Acute Myeloid Leukaemia

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:00 AM
Duration 10mins Hall C2-C3
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers C, Salles G
Haematology - Oncology | Diffuse Large B-Cell Lymphoma

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

Sign up or login to unlock the full suite of MEDICALLY features
ASH 2021 In-Depth Report: Leukaemia
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
ASH 2021 In-Depth Report: Lymphoma
Springer Healthcare
Open asset

Sign up or login to unlock the full suite of MEDICALLY features
ASH 2021 In-Depth Report: Haemophilia
Springer Healthcare
Open asset

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.